Nov. 27, 2002 — Surface Logix Inc. said it has raised $25 million in a two-part, third round of funding.
The Boston-based developer of microfabrication and chemistry technologies for drug discovery platforms, said new investor HBM BioVentures led the round, joined by others including the California Public Employees’ Retirement System, Intel Capital and TIAA-CREF. Existing investors Arch Venture Partners, CW Group and Venrock Associates also participated.
Surface Logix officials said they will use the money to continue development of its Disease Interrogator platform while pursuing partnerships with other companies in the areas of inflammation and oncology.